The Heifets Laboratory
Welcome to the Heifets Lab
Our research group is dedicated to understanding and improving on powerful, rapid-acting therapies for psychiatric disease, such as ketamine, MDMA and psilocybin. We bridge basic science and clinical trials, connecting neuroscience, psychiatry and anesthesiology in pursuit of highly effective, safe treatment strategies scalable to the millions of patients who need them.
Follow Us on Twitter
The positive topline results from our Phase 3 Emerge clinical trial represent more than a company milestone, they reflect growing momentum toward potential new treatment possibilities for people living with major depressive disorder (MDD).
Hear from Emerge Principal Investigator
Ketamine's noticeable side effects can make it difficult to know whether improvements in pain and depression come from the drug itself or from patients knowing they received it. In an early study, researchers tested a new approach using the sedative propofol to keep participants
We all thought this study would fail, for different reasons.
Joe Taylor (1st author) thought it'd be a takedown of fMRI-guided TMS.
@foxmdphd and I (co-senior authors) thought the effect would be too small to detect in just 40 patients.
We were wrong.
Connectivity- vs Scalp-Based Targeting of Accelerated TMS for Depression
This randomized clinical trial estimates the effect size of connectivity- vs scalp-based targeting of accelerated transc...
jamanetwork.com
Hey psychedelic researchers, do you know any company that supplies 1mg and higher quantities of psilocybin?
New work on the effects of psychedelics on hierarchical cortical propagations out in PNAS!
Counter to our expectations, psychedelics attenuated bottom-up propagations into the Default Mode Network across substances and species. Thread below:
Psychedelics disrupt hierarchical cortical propagations in the default mode network of humans and...
Psychedelic drugs are poised to become mainstream treatments, yet we lack a circuit-level account of how they reshape brain activity. Emerging evid...
www.pnas.org
For more info visit Heifets Lab @StanfordMed, and to read the journal article, click here:
Feasibility of a Multicomponent Protocol to Promote... : Anesthesiology
acilitate a preemergence state conducive to dreaming, integrating it into routine care to assess adherence, dream reca...
journals.lww.com
What do we know about #dreaming while under surgical #anesthesia? ICYMI: Primary Care Medicine's @marinakurian & @rachel_rdn spoke with Dr. Boris Heifets @StanfordMed @TheBorisLab Tue 6/16 from 9-9:30amET LIVE about his new study in @_Anesthesiology about inducing #dreaming.
JHU PhD student Katherine Cheung and PhD Candidate Caleigh Propes, with CPCR Associate Professor Dr. David Yaden, evaluated comparison sets on the price of Oregon’s psilocybin services. As the first state in the U.S. to legalize psilocybin access and a key reference point on how
CPCR Associate Director Dr. Albert Garcia-Romeu weighed in on a recent case report of psilocybin administration for an individual with suspected Alzheimer's Disease, noting some important concerns about the report: “We currently have no rigorous evidence for clinical benefits of